Phase II study of hepatic arterial infusion of cisplatin for unresectable intrahepatic cholangiocarcinoma

Phase II study of hepatic arterial infusion of cisplatin for unresectable intrahepatic cholangiocarcinoma - ICC-CDDP

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000809

Enrollment

Registered

2007-08-31

Start date

2007-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

intrahepatic cholangiocarcinoma

Interventions

CDDP is administered at a dose of 65 mg/m2 into the hepatic artery. The treatment is repeated every 4 to 6 weeks until a maximum of 6 courses, the appearance of unacceptable toxicity, or disease progr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) histologically confirmed ICC 2) unresectable or recurrent disease 3) ECOG Performance Status 0-1 4) having measurable lesion 5) adequate organ function 6) no prior chemotherapy using platinum compound 7) no prior radiotherapy 8) written informed consent

Exclusion criteria

Exclusion criteria: 1) presence of uncontrollable ascites or pleural effusion 2) cerebral or bone metastasis 3) uncontrollable cardiovascular disease or prior myocardial infarction 4) active infection other than HBV or HCV 5) other malignancy 6) severe psychiatric disorder 7) severe drug allergy 8) pregnant or nursing

Design outcomes

Primary

Measure	Time frame
response rate	—

Secondary

Measure	Time frame
adverse events, overall survival, progression free survival	—

Countries

Japan

Contacts

Public ContactKohei Nakachi

Sapporo Medical University Gastroenterology

knakachi-gi@umin.org0155-22-6600

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026